Which action would the nurse take to decrease the risk of transmission of vancomycin resistant enterococci VRE )?

1. Aarestrup F M. Occurrence of glycopeptide resistance among Enterococcus faecium isolates from conventional and ecological poultry farms. Microb Drug Resist. 1995;1:255–257. [PubMed] [Google Scholar]

2. Reference deleted.

3. Reference deleted.

4. Reference deleted.

5. Reference deleted.

6. Al-Obeid S, Billot-Klein D, van Heijenoort J, Collatz E, Gutmann L. Replacement of the essential penicillin-binding protein 5 by high-molecular mass PBPs may explain vancomycin-β-lactam synergy in low-level vancomycin-resistant Enterococcus faecium D366. FEMS Microbiol Lett. 1992;91:79–84. [PubMed] [Google Scholar]

7. Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993;37:1563–1571. [PMC free article] [PubMed] [Google Scholar]

8. Arthur M, Depardieu F, Gerbaud G, Gallimand M, Leclercq R, Courvalin P. The VanS sensor negatively controls VanR-mediated transcriptional activation of glycopeptide resistance genes of Tn1546 and related elements in the absence of induction. J Bacteriol. 1997;179:97–106. [PMC free article] [PubMed] [Google Scholar]

9. Arthur M, Depardieu F, Molinas C, Reynolds P, Courvalin P. The vanZ gene of Tn1546 from Enterococcus BM4147 confers resistance to teicoplanin. Gene. 1995;154:87–92. [PubMed] [Google Scholar]

10. Arthur M, Depardieu F, Reynolds P, Courvalin P. Quantitative analysis of the metabolism of soluble cytoplasmic peptidoglycan precursors of glycopeptide resistance enterococci. Mol Microbiol. 1996;21:33–44. [PubMed] [Google Scholar]

11. Arthur M, Molinas C, Depardieu F, Courvalin P. Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol. 1993;175:117–127. [PMC free article] [PubMed] [Google Scholar]

12. Arthur M, Molinas C, Dutka-Malen S, Courvalin P. Structural relationship between the vancomycin resistance protein VanH and 2-hydroxycarboxylic acid dehydrogenases. Gene. 1991;103:133–134. [PubMed] [Google Scholar]

13. Bailey E M, Rybak M J, Kaatz G W. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother. 1991;35:1089–1092. [PMC free article] [PubMed] [Google Scholar]

14. Baltch A, Smith R P, Bopp L H. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1998;42:2564–2568. [PMC free article] [PubMed] [Google Scholar]

15. Baptista M, Depardieu F, Courvalin P, Arthur M. Specificity of induction of glycopeptide resistance genes in Enterococcus faecalis. Antimicrob Agents Chemother. 1996;40:2291–2295. [PMC free article] [PubMed] [Google Scholar]

16. Barbier N, Saulnier P, Chachaty E, Dumontier S, Andremont A. Random amplified polymorphic DNA typing versus pulsed-field gel electrophoresis for epidemiological typing of vancomycin-resistant enterococci. J Clin Microbiol. 1996;34:1096–1099. [PMC free article] [PubMed] [Google Scholar]

17. Reference deleted.

18. Bartoloni A, Colao M G, Orsi A, Dei R, Giganti E, Parenti F. In vitro activity of vancomycin, teicoplanin, daptomycin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile. J Antimicrob Chemother. 1990;26:627–633. [PubMed] [Google Scholar]

19. Bates J, Jordens J Z, Griffiths D T. Farm animals as putative reservoir for vancomycin-resistant enterococcal infection in man. Antimicrob Agents Chemother. 1995;39:781–785. [Google Scholar]

20. Reference deleted.

21. Beezhold D W, Slaughter S, Hayden M K, Matushek M, Nathan C, Trenholme G M, Weinstein R A. Skin colonization with vancomycin-resistant enterococci among hospitalized patients with bacteremia. Clin Infect Dis. 1997;24:704–706. [PubMed] [Google Scholar]

22. Biavasco F, Manso E, Varaldo P E. In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 1991;35:195–197. [PMC free article] [PubMed] [Google Scholar]

23. Biavasco F, Vignaroli C, Lupidi R, Manso E, Facinelli B, Varaldo P E. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob Agents Chemother. 1997;41:2165–2172. [PMC free article] [PubMed] [Google Scholar]

24. Billot-Klein D, Gutmann L, Sable S, Guittet E, van Heijenoort J. Modification of peptidoglycan precursors is a common feature of the low-level vancomycin-resistant VanB type enterococcus D366 and of the naturally glycopeptide-resistant species Lactobacillus casei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Enterococcus gallinarum. J Bacteriol. 1994;176:2398–2405. [PMC free article] [PubMed] [Google Scholar]

25. Bingen E, Doit C, Lambert-Zechovsky N, Tod M, Petitjean O, Bourgeois F, Mariani-Kurkdjian P, et al. Bactericidal activity of daptomycin against vancomycin-resistant Enterococcus faecium in an in vitro pharmacokinetic model. Eur J Clin Microbiol Infect Dis. 1991;10:1062–1065. [PubMed] [Google Scholar]

26. Bingen E, Lambert-Zechovsky N, Leclercq R, Doit C, Mariani-Kurkdjian P. Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother. 1990;26:619–626. [PubMed] [Google Scholar]

27. Bonilla H F, Zervos M A, Lyons M J, Bradley S F, Hedderwick S A, Ramsey M A, Paul L K, Kauffman C A. Colonization with vancomycin-resistant Enterococcus faecium: comparison of a long-term-care unit with an acute hospital. Infect Control Hosp Epidemiol. 1997;18:333–339. [PubMed] [Google Scholar]

28. Bostic G D, Perri L A, Thal L A, Zervos M J. Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci. Diagn Microbiol Infect Dis. 1998;30:109–112. [PubMed] [Google Scholar]

29. Boyce J M, Mermel L A, Zervos M J, Rice L B, Potter-Bynoe G, Giorgio C, Medeiros A A. Controlling vancomycin-resistant enterococci. Infect Control Hosp Epidemiol. 1995;16:634–637. [PubMed] [Google Scholar]

30. Boyce J M, Opal S M, Chow J W, Zervos M J, Potter-Bynoe G, Sherman C B, Romulo R L, Fortna S, Medeiros A A. Outbreak of multi-drug resistant Enterococcus faecium with transferable VanB class vancomycin resistance. J Clin Microbiol. 1994;32:1148–1153. [PMC free article] [PubMed] [Google Scholar]

31. Boyce J M. Vancomycin-resistant enterococci: pervasive and persistent pathogens. Infect Control Hosp Epidemiol. 1995;116:676–679. [PubMed] [Google Scholar]

32. Boyce J M. Vancomycin-resistant enterococcus: detection, epidemiology and control measures. Infect Dis Clin North Am. 1997;11:367–384. [PubMed] [Google Scholar]

33. Boyle J F, Soumakis S A, Rondo A, Herrington J A, Gianarkis D G, Thurberg B E, Painter B G. Epidemiologic analysis and genotypic characterization of nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol. 1993;32:1280–1285. [PMC free article] [PubMed] [Google Scholar]

34. Brandt C M, Rouse M S, Laue N W, Stratton C W, Wilson W R, Steckelberg J M. Effective treatment of multi-drug resistant enterococcal experimental endocarditis with combinations of cell-wall active agents. J Infect Dis. 1996;173:909–913. [PubMed] [Google Scholar]

35. Brennen C, Wagener M M, Muder R R. Vancomycin-resistant Enterococcus faecium in a long-term-care facility. J Am Geriatr Soc. 1998;46:157–160. [PubMed] [Google Scholar]

36. Bugg T D H, Dutka-Malen S, Arthur M, Courvalin P, Walsh C T. Identification of vancomycin resistance protein VanA as a d-alanine-d-alanine ligase of altered substrate specificity. Biochemistry. 1991;30:2017–2021. [PubMed] [Google Scholar]

37. Bugg T D H, Wright G D, Dutka-Malen S, Arthur M, Courvalin P, Walsh C T. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry. 1991;30:1408–1415. [PubMed] [Google Scholar]

38. Burney S, Landman D, Quale J M. Activity of clinafloxacin against multidrug-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1994;38:68–70. [PMC free article] [PubMed] [Google Scholar]

39. Buschelman B J, Jones R N. Newer glycopeptide antibiotics tested against nosocomial bloodstream isolates. J Antimicrob Chemother. 1993;31:445–447. [PubMed] [Google Scholar]

40. Butz A M, Laughon B E, Gulette D L, Larson E. Alcohol impregnated wipes as an alternative in hand hygiene. Am J Infect Control. 1990;18:70–76. [PubMed] [Google Scholar]

41. Caron F, Carbon C, Gutmann L. Triple combination of penicillin-vancomycin-gentamicin for experimental endocarditis caused by a moderately penicillin- and highly glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis. 1994;164:888–893. [PubMed] [Google Scholar]

42. Caron F, Pestel M, Kitzis M D, Lemeland J F, Hambert G, Gutmann L. Comparison of different β-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly β-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis. 1995;17:106–112. [PubMed] [Google Scholar]

43. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin—United States, 1989–1993. Morb Mortal Weekly Rep. 1993;42:597–599. [PubMed] [Google Scholar]

44. Centers for Disease Control and Prevention. Recommendations for preventing spread of vancomycin resistance. Infect Control Hosp Epidemiol. 1995;16:105–113. [PubMed] [Google Scholar]

45. Cercenado A, Eliopoulos G M, Wennersten C B, Moellering R C., Jr Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci. Antimicrob Agents Chemother. 1992;36:2201–2203. [PMC free article] [PubMed] [Google Scholar]

46. Reference deleted.

47. Chia J K S, Nakata M M, Park S S, Lewis R P, McKnee B. Use of bacitracin therapy for infection due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis. 1995;21:1520. [PubMed] [Google Scholar]

48. Chin N X, Neu H C. Neu. In vitro activity of LY 264826 compared to other glycopeptides and daptomycin. Diagn Microbiol Infect Dis. 1991;14:181–184. [PubMed] [Google Scholar]

49. Chow J W, Davidson A, Sanford III E, Zervos M J. Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy. Clin Infect Dis. 1997;24:91–92. [PubMed] [Google Scholar]

50. Chow J W, Donabedian S M, Zervos M J. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin Infect Dis. 1997;24:90–91. [PubMed] [Google Scholar]

51. Clark N C, Cooksey R C, Hill B C, Swenson J M, Tenover F C. Characterization of glycopeptide-resistant enterococci from US hospitals. Antimicrob Agents Chemother. 1993;37:2311–2317. [PMC free article] [PubMed] [Google Scholar]

52. Clark N C, Teixeira L M, Facklam R R, Tenover F C. Detection and differentiation of vanC-1, vanC-2, and vanC-3 glycopeptide resistance genes in enterococci. J Clin Microbiol. 1998;36:2294–2297. [PMC free article] [PubMed] [Google Scholar]

53. Clevel D B. Movable genetic elements and antibiotic resistance in enterococci. Eur J Clin Microbiol Infect Dis. 1990;9:90–102. [PubMed] [Google Scholar]

54. Collins L A, Eliopoulos G M, Wennersten C B, Ferraro M J, Moellering R C., Jr In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother. 1993;37:1364–1366. [PMC free article] [PubMed] [Google Scholar]

55. Collins L A, Malanoski G J, Eliopoulos G M, Wennersten C B, Ferraro M J, Moellering R C. In vitro activity of RP 59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother. 1993;37:598–601. [PMC free article] [PubMed] [Google Scholar]

56. Cooper R D G, Snyder N J, Zweifel M J, Staszak A, Wilkie S C, Nicas T, Mullen D L, Butler T F, Rodriguez M J, Huff B E, Thompson R C. Reductive alkylation of glycopeptide antibiotics-synthesis and antibacterial activity. J Antibiot (Tokyo) 1996;49:575–581. [PubMed] [Google Scholar]

57. Courvalin P. Resistance of enterococci to glycopeptides. Antimicrob Agents Chemother. 1990;34:2291–2294. [PMC free article] [PubMed] [Google Scholar]

58. Crossley K. Vancomycin-resistant enterococci in long-term-care facilities. Infect Control Hosp Epidemiol. 1998;19:521–525. [PubMed] [Google Scholar]

59. Reference deleted.

60. Dahl K H, Simonsen G S, Olsvik Ø, Sundsfjord A. Heterogeneity in the vanB gene cluster of genomically diverse clinical strains of vancomycin-resistant enterococci. Antimicrob Agents Chemother. 1999;43:1105–1110. [PMC free article] [PubMed] [Google Scholar]

61. Dahms R A, Johnson E M, Statz C L, Lee J T, Dunn D L, Beilman G J. Third generation cephalosporins and vancomycin as risk factors for postoperative vancomycin-resistant Enterococcus infection. Arch Surg. 1998;133:1343–1346. [PubMed] [Google Scholar]

62. Daly J S, Eliopoulos G M, Willey S, Moellering R C., Jr Mechanism for action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother. 1988;32:1341–1346. [PMC free article] [PubMed] [Google Scholar]

63. DeGroot-Kosolcharoen J, Jones J M. Permeability of latex and vinyl glove to water and blood. Am J Infect Control. 1989;17:196–201. [PubMed] [Google Scholar]

64. Dever L L, Smith S M, Handwerger S, Eng R H K. Vancomycin-dependent Enterococcus faecium isolated from stool following oral vancomycin therapy. J Clin Microbiol. 1995;33:2770–2273. [PMC free article] [PubMed] [Google Scholar]

65. Devriese L A, Ieven M, Goosens H, Vandamme P, Pot B, Hommez J, Haesebrouck F. Presence of vancomycin-resistant enterococci in farm and pet animals. Antimicrob Agents Chemother. 1996;40:2285–2287. [PMC free article] [PubMed] [Google Scholar]

66. Doebbeling B N, Stanley G L, Sheetz C T, Pfaller M A, Houston A K, Annis L, Li N, Wenzel R P. Comparative efficacy of alternative hand-washing agents in reducing nosocomial infections in intensive care units. N Engl J Med. 1992;327:88–93. [PubMed] [Google Scholar]

67. Reference deleted.

68. Dutka-Malen S, Blaimont B, Wauters G, Courvalin P. Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob Agents Chemother. 1994;38:1675–1677. [PMC free article] [PubMed] [Google Scholar]

69. Dutka-Malen S, Evers S, Courvalin P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol. 1995;33:24–27. [PMC free article] [PubMed] [Google Scholar]

70. Edmond M B, Ober J F, Dawson J D, Weinbaum D L, Wenzel R P. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis. 1996;23:1234–1239. [PubMed] [Google Scholar]

71. Edmond M B, Ober J F, Weinbaum D L, Pfaller M A, Hwang T, Sanford M D, Wenzel R P. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis. 1995;20:1126–1133. [PubMed] [Google Scholar]

72. Reference deleted.

73. Eliopoulos G M, Eliopoulos C T. Therapy of enterococcal infections. Eur J Clin Microbiol Infect Dis. 1990;91:18–26. [Google Scholar]

74. Eliopoulos G M, Wennersten C B, Cole G, Moellering R C. Antimicrobial activity of two glycylcyclines against gram-positive bacteria. Antimicrob Agents Chemother. 1994;38:534–541. [PMC free article] [PubMed] [Google Scholar]

75. Eliopoulos G M, Wennersten C B, Gold H S, Moellering R C. In vitro activities of new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother. 1996;40:1745–1747. [PMC free article] [PubMed] [Google Scholar]

76. Eliopoulos G M, Willey G, Murray B E, Moellering R C. Ciprofloxacin in experimental endocarditis due to a beta-lactamase producing highly gentamicin-resistant strain of E. faecalis. Rev Infect Dis. 1989;11(Suppl. 5):1210–1211. [Google Scholar]

77. Eliopoulos G M. Aminoglycoside-resistant enterococcal endocarditis. Infect Dis Clin North Am. 1993;7:117–133. [PubMed] [Google Scholar]

78. Eliopoulos G M. Antibiotic resistance in Enterococcus species: an update. In: Remington J S, Swartz M N, editors. Current topics in infectious diseases. Vol. 16. Boston, Mass: Blackwell Scientific Publications Ltd.; 1996. pp. 21–51. [PubMed] [Google Scholar]

79. Eliopoulos G M. Increasing problems in the therapy of enterococcal infections. Eur J Clin Microbiol Infect Dis. 1993;12:409–412. [PubMed] [Google Scholar]

80. Eliopoulos G M. Vancomycin-resistant enterococci: mechanism and clinical relevance. Infect Dis Clin North Am. 1997;11:851–865. [PubMed] [Google Scholar]

81. Reference deleted.

82. El-Mady A, Mortensen J E. The bactericidal activity of ampicillin, daptomycin, and vancomycin against ampicillin-resistant Enterococcus faecium. Diagn Microbiol Infect Dis. 1991;14:141–145. [PubMed] [Google Scholar]

83. Ena J, Dick R W, Jones R N, Wenzel R P. The epidemiology of intravenous vancomycin usage in a university hospital. JAMA. 1993;269:598–602. [PubMed] [Google Scholar]

84. Endtz H P, Van Den Braak N, Van Belkum A, Goessens Wil H, Kreft D, Stroebel A B, Verbrugh H A. Comparison of eight methods to detect vancomycin resistance in enterococci. J Clin Microbiol. 1998;36:592–594. [PMC free article] [PubMed] [Google Scholar]

85. Everitt D E, Soumerai S B, Avorn J, Klapholz H, Wessels M. Changing surgical antimicrobial prophylaxis practices through education targeted at senior department leaders. Infect Control Hosp Epidemiol. 1990;11:578–583. [PubMed] [Google Scholar]

86. Evers S, Courvalin P. Regulation of VanB type vancomycin resistance gene expression by the VanSB-VanRB two-component regulatory system in Enterococcus faecalis V583. J Bacteriol. 1996;178:1302–1309. [PMC free article] [PubMed] [Google Scholar]

87. Evers S, Sahm D F, Courvalin P. The vanB gene of Enterococcus faecalis V583 is structurally related to genes encoding d-Ala, d-Ala ligases and glycopeptide-resistance proteins VanA and VanC. Gene. 1993;124:143–144. [PubMed] [Google Scholar]

88. Reference deleted.

89. Favero M S, Bond W W. Sterilization, disinfection and antisepsis in the hospital. In: Balows A, Hausler W J Jr, Herrmann K L, Isenberg H D, Shadomy H J, editors. Manual of clinical microbiology. 5th ed. Washington, D.C.: American Society for Microbiology; 1991. pp. 183–200. [Google Scholar]

90. Fekety R. Vancomycin and teicoplanin. In: Mandell G L, Bennett J E, Dolin R, editors. Principles and practice of infectious diseases. 4th ed. New York, N.Y: Churchill Livingstone, Inc.; 1995. pp. 346–354. [Google Scholar]

91. Felmingham D. Towards the ideal glycopeptide. J Antimicrob Chemother. 1993;32:663–666. [PubMed] [Google Scholar]

92. Fernandez-Guerrero M L, Rouse S M, Henry N K, Geraci J E, Wilson W R. In vitro and in vivo activity of ciprofloxacin against enterococci isolated from patients with infective endocarditis. Antimicrob Agents Chemother. 1987;31:430–433. [PMC free article] [PubMed] [Google Scholar]

93. Fernandez-Guerrero M L, Barros C, Rodriguez Tudella J L, Soriano F. Aortic endocarditis caused by gentamicin-resistant Enterococcus faecalis. Eur J Clin Microbiol Infect Dis. 1988;7:525–752. [PubMed] [Google Scholar]

94. Fines M, Perichon B, Reynolds P, Sahm D F, Courvalin P. VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405. Antimicrob Agents Chemother. 1999;43:2161–2164. [PMC free article] [PubMed] [Google Scholar]

95. Fontana R, Bertolini G, Amalfitano G, Canepari P. Characterization of penicillin-resistant Streptococcus faecium mutants. FEMS Microbiol Lett. 1984;25:21–25. [Google Scholar]

96. Fontana R, Cerini R, Longoni P, Grossato A, Canepari P. Identification of a streptococcal penicillin-binding protein that reacts very slowly with penicillin. J Bacteriol. 1983;155:1343–1350. [PMC free article] [PubMed] [Google Scholar]

97. Fontana R, Grossata A, Rossi L, Cheng Y R, Satta G. Transition from resistance to hypersusceptibility to β-lactam antibiotics associated with loss of a lower-affinity penicillin-binding protein in a Streptococcus faecium mutant highly resistant to penicillin. Antimicrob Agents Chemother. 1985;28:678–683. [PMC free article] [PubMed] [Google Scholar]

98. Fraimow H S, Venuti E. Inconsistent bactericidal activity of triple-combination therapy with vancomycin, ampicillin, and gentamicin against vancomycin-resistant, highly ampicillin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1992;36:1563–1566. [PMC free article] [PubMed] [Google Scholar]

99. Fraise A P, Brenwald N, Andrews J M, Wise R. In vitro activity of two glycylcyclines against enterococci resistant to other agents. J Antimicrob Chemother. 1995;35:877–881. [PubMed] [Google Scholar]

100. Freeman R, Gould F K, Ryan D W, Chamberlain J, Sisson P R. Nosocomial infection due to enterococci attributed to a fluidized microsphere bed. The value of pyrolysis mass spectrometry. J Hosp Infect. 1994;27:187–193. [PubMed] [Google Scholar]

101. Freeman R, Kearns A M, Lighfoot N F. Heat resistance of nosocomial enterococci. Lancet. 1994;344:64–65. [PubMed] [Google Scholar]

102. Reference deleted.

103. French P, Venuti E, Frainow H S. In vitro activity of novobiocin against multiresistant strains of Enterococcus faecium. Antimicrob Agents Chemother. 1993;37:2736–2739. [PMC free article] [PubMed] [Google Scholar]

104. Friden T R, Munsiff S S, Low D E, Willey B M, William G, Faur Y, Eisner W, Warren S, Kreiswirth B. Emergence of vancomycin-resistant enterococci in New York City. Lancet. 1993;342:76–79. [PubMed] [Google Scholar]

105. Reference deleted.

106. Garner J S, Simmons B P. CDC guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol. 1983;4:245–325. [PubMed] [Google Scholar]

107. Garner J S for the Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol. 1996;17:53–80. [PubMed] [Google Scholar]

108. Garrison M W, Rotschafer J C, Crossley K B. Suboptimal effects of daptomycin in the treatment of bacteremias. South Med J. 1989;82:1414–1415. [PubMed] [Google Scholar]

109. Gold H S, Moellering R C., Jr Antimicrobial drug resistance. N Engl J Med. 1996;335:1445–1453. [PubMed] [Google Scholar]

110. Gordon S, Swenson J M, Hill B C, Piggot N E, Facklau R R, Cooksey R C, Thornsberry C, Jarvis W R, Tenover F C. Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. J Clin Microbiol. 1992;30:2373–2378. [PMC free article] [PubMed] [Google Scholar]

111. Gordst B, van Landuyt H, Ieven M, van Damme P, Goossens H. Vancomycin-resistant enterococci colonizing the intestinal tracts of hospitalized patients. J Clin Microbiol. 1995;33:2842–2846. [PMC free article] [PubMed] [Google Scholar]

112. Gould F K, Freeman R. Nosocomial infection with microsphere beds. Lancet. 1993;342:241–242. [PubMed] [Google Scholar]

113. Grayson M L, Eliopoulos G M, Wennersten C B, Ruoff K L, De Girolami P C, Ferraro M J, Moellering R C., Jr Increasing resistance to β-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review in one institution. Antimicrob Agents Chemother. 1991;35:2180–2184. [PMC free article] [PubMed] [Google Scholar]

114. Green M, Barbadora K, Michaels M. Recovery of vancomycin-resistant gram-positive cocci from pediatric liver transplant recipients. J Clin Microbiol. 1991;29:2503–2506. [PMC free article] [PubMed] [Google Scholar]

115. Green M, Shlaes J H, Barbadora K, Shlaes D M. Bacteremia due to vancomycin-dependent Enterococcus faecium. Clin Infect Dis. 1995;20:712–714. [PubMed] [Google Scholar]

116. Hamilton-Miller J M T. In vitro activity of fosfomycin against problem gram-positive cocci. Microbios. 1992;71:95–103. [PubMed] [Google Scholar]

117. Handwerger S, Kolokathis A. Induction of vancomycin resistance in Enterococcus faecium by inhibition of transglycosylation. FEMS Microbiol Lett. 1990;58:167–170. [PubMed] [Google Scholar]

118. Handwerger S, Perlman D C, Altarac D, McAuliffe V. Concomitant high-level vancomycin and penicillin resistance in clinical isolates of enterococci. Clin Infect Dis. 1992;14:655–661. [PubMed] [Google Scholar]

119. Handwerger S, Pucci M J, Kolokathis A. Vancomycin resistance is encoded on a pheremone response plasmid in Enterococcus faecium 228. Antimicrob Agents Chemother. 1990;34:358–360. [PMC free article] [PubMed] [Google Scholar]

120. Handwerger S, Pucci M J, Volk K J, Liu J, Lee M S. Vancomycin-resistant Leuconostoc mesenteroides and Lactobacillus casei synthesize cytoplasmic peptidoglycan precursors that terminate in lactate. J Bacteriol. 1994;176:260–264. [PMC free article] [PubMed] [Google Scholar]

121. Handwerger S, Raucher B, Altarac D, Manka J, Marchione S, Sing K V, Murray B E, Wolff J, Walters B. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis. 1993;16:750–755. [PubMed] [Google Scholar]

122. Handwerger S, Skoble J, Discotto L F, Pucci M J. Heterogeneity of the vanA gene in clinical isolates of enterococci from the Northeastern United States. Antimicrob Agents Chemother. 1995;39:362–368. [PMC free article] [PubMed] [Google Scholar]

123. Handwerger S, Skoble J. Identification of chromosomal mobile element conferring high-level vancomycin resistance in Enterococcus faecium. Antimicrob Agents Chemother. 1995;39:2446–2453. [PMC free article] [PubMed] [Google Scholar]

124. Reference deleted.

125. Hayden M K, Koenig G I, Trenholme G M. Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations. Antimicrob Agents Chemother. 1994;38:1225–1229. [PMC free article] [PubMed] [Google Scholar]

126. Hayden M K, Trenholme G M, Schultz J E, Sahm D F. In vivo development of teicoplanin resistance in VanB Enterococcus faecium isolate. J Infect Dis. 1993;167:1224–1227. [PubMed] [Google Scholar]

127. Herman D J, Gerding D N. Screening and treatment of infections caused by resistant enterococci. Antimicrob Agents Chemother. 1991;35:215–219. [PMC free article] [PubMed] [Google Scholar]

128. Ikeda D P, Barry A A L, Anderson S G. Emergence of Streptococcus faecalis isolates with high-level resistance to multiple aminocyclitol aminoglycosides. Diagn Microbiol Infect Dis. 1984;2:171–177. [PubMed] [Google Scholar]

129. Ingerman M J, Santoro J. Vancomycin: a new old agent. Infect Dis Clin North Am. 1989;3:641–651. [PubMed] [Google Scholar]

130. Jamjian C, Biedenbach D J, Jones R N. In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004. Antimicrob Agents Chemother. 1997;41:454–459. [PMC free article] [PubMed] [Google Scholar]

131. Johnson C C, Slavoski L, Schwartz M, May P, Pitsakis P G, Shur A L, Levison M E. In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci. Diagn Microbiol Infect Dis. 1995;21:169–173. [PubMed] [Google Scholar]

132. Johnson C C, Taylor S, Pitsakis P, May P, Levison M E. Bactericidal activity of ramoplanin against antibiotic-resistant gram-positive cocci. Antimicrob Agents Chemother. 1992;36:2342–2345. [PMC free article] [PubMed] [Google Scholar]

133. Jones M V, Rowe G B, Jackson B, Pritchard N J. The use of alcohol paper wipes for routine hand cleansing: results of trials in two hospitals. J Hosp Infect. 1986;8:268–274. [PubMed] [Google Scholar]

134. Jones R N, Erwin M E, Anderson S C. Emerging multiply resistant enterococci among clinical isolates: validation of E test to recognize glycopeptide-resistant strains. Diagn Microbiol Infect Dis. 1995;21:95–100. [PubMed] [Google Scholar]

135. Jordens J Z, Bates J, Griffiths D T. Faecal carriage and nosocomial spread of vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother. 1994;34:515–528. [PubMed] [Google Scholar]

136. Kang S L, Rybak M J. Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model. Antimicrob Agents Chemother. 1995;39:1505–1511. [PMC free article] [PubMed] [Google Scholar]

137. Karanfil L V, Murphy M, Josephson A, Gaynes R, Mandel L, Hill B C, Swenson J M. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol. 1992;13:195–200. [PubMed] [Google Scholar]

138. Kearns A M, Freeman R, Lightfoot N F. Nosocomial enterococci: resistance to heat and sodium hypochloride. J Hosp Infect. 1995;30:193–199. [PubMed] [Google Scholar]

139. Klare I, Heier H, Claus H, Bohme G, Marin S, Seltmann G, Hakenbeck R, Santanassova V, Witte W. Enterococcus faecium strains with vanA-mediated high-level glycopeptide resistance isolated from foodstuffs and fecal samples of humans in the community. Microb Drug Resist. 1995;1:265–272. [PubMed] [Google Scholar]

140. Klare I, Heier H, Claus H, Reissbrodt R, Witte W. vanA mediated high-level glycopeptide resistance in Enterococcus faecium from animal husbandry. FEMS Microbiol Lett. 1995;125:165–172. [PubMed] [Google Scholar]

141. Korniewicz D M, Kirwin M, Cresci K, Markut C, Larson E. In-use comparison of latex gloves in two high-risk units: surgical intensive care and acquired immunodeficiency syndrome. Heart Lung. 1992;21:81–84. [PubMed] [Google Scholar]

142. Korniewicz D M, Laughon B E, Butz A, Larson E. Integrity of vinyl and latex procedure gloves. Nurs Res. 1989;38:144–146. [PubMed] [Google Scholar]

143. Korniewicz D M, Laughon B E, Cyr W H, Lytle C D, Larson E. Leakage of virus through used vinyl and latex examination gloves. J Clin Microbiol. 1990;28:787–788. [PMC free article] [PubMed] [Google Scholar]

144. Krogstad D J, Parquette A R. Detective killing of enterococci: a common property of antimicrobial agents acting on the cell wall. Antimicrob Agents Chemother. 1980;17:965–968. [PMC free article] [PubMed] [Google Scholar]

145. Lai K K, Kelly A L, Melvin Z S, Belliveau P P, Fontecchio S A. Failure to eradicate vancomycin-resistant enterococci in a university hospital and the cost of barrier precautions. Infect Control Hosp Epidemiol. 1998;19:647–652. [PubMed] [Google Scholar]

146. Lai M H, Kirsch D R. Induction signals for vancomycin resistance encoded by the vanA gene cluster in Enterococcus faecium. Antimicrob Agents Chemother. 1996;40:1645–1648. [PMC free article] [PubMed] [Google Scholar]

147. Lam S, Singer C, Tucci V, Morthland V H, Pfaller M A, Isenberg H D. The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study. Am J Infect Control. 1995;23:170–180. [PubMed] [Google Scholar]

148. Lamp K C, Rybak M J, Bailey E M, Kaatz G W. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother. 1992;36:2709–2714. [PMC free article] [PubMed] [Google Scholar]

149. Lancefield R C. Serological differentiation of human and other groups of haemolytic streptococci. J Exp Med. 1933;57:571–595. [PMC free article] [PubMed] [Google Scholar]

150. Landman D, Mobarakai N K, Quale J M. Novel antibiotic regimens against Enterococcus faecium resistant to ampicillin, vancomycin, and gentamicin. Antimicrob Agents Chemother. 1993;37:1904–1908. [PMC free article] [PubMed] [Google Scholar]

151. Larson E. Compliance with isolation technique. Am J Infect Control. 1983;11:221–225. [PubMed] [Google Scholar]

152. Lautenbach E, Bilker W, Brennan P J. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol. 1999;20:318–323. [PubMed] [Google Scholar]

153. Leclercq R, Bingen E, Su Q H, Lamber-Zechovski N, Courvalin P, Duval J. Effects of combinations of β-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother. 1991;35:92–98. [PMC free article] [PubMed] [Google Scholar]

154. Leclercq R, Courvalin P. Resistance to glycopeptides in enterococci. Clin Infect Dis. 1997;24:545–556. [PubMed] [Google Scholar]

155. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med. 1988;319:157–160. [PubMed] [Google Scholar]

156. Leclercq R. Enterococci acquire new kinds of resistance. Clin Infect Dis. 1997;24(Suppl. 1):S80–S84. [PubMed] [Google Scholar]

157. Lee B L, Sachdeva M, Chambers H F. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob Agents Chemother. 1991;35:2505–2508. [PMC free article] [PubMed] [Google Scholar]

158. Lewis C M, Zervos M J. Clinical manifestations of enterococcal infection. Eur J Clin Microbiol Infect Dis. 1990;9:111–117. [PubMed] [Google Scholar]

159. Lin A H, Murray R W, Widmar T J, Marotti A R. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with the binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother. 1997;41:217–231. [PMC free article] [PubMed] [Google Scholar]

160. Reference deleted.

161. Linden P K, Pasculle A W, Maneaz R, Kramer D J, Fung J J, Pinna A D, Kusne S. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis. 1996;22:663–670. [PubMed] [Google Scholar]

162. Linden P K, Pasculle A W, McDewitt D, Kramer D J. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteremia: comparison with a control cohort. J Antimicrob Chemother. 1997;39(Suppl. A):145–151. [PubMed] [Google Scholar]

163. Liu J, Volk K J, Lee M S, Pucci M, Handwerger S. Binding studies of vancomycin to the cytoplasmic peptidoglycan precursors by affinity capillary electrophoresis. Anal Chem. 1994;66:2412–2416. [PubMed] [Google Scholar]

164. Livornese L L, Dias S, Samel C, Romanowski B, Taylor S, May P, Pitsakis P, Woods G, Kaye D, Levison M E. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med. 1992;117:112–116. [PubMed] [Google Scholar]

165. Luber A D, Jacobs R A, Jordan M, Guglielmo B J. Relative importance of oral versus intravenous vancomycin exposure in the development of vancomycin-resistant enterococci. J Infect Dis. 1996;173:1292–1293. [PubMed] [Google Scholar]

166. Lynn W A, Clutterbuck E, Want S, Markides V, Lacey S, Rogers T R, Cohen J. Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinipristin/dalfopristin. Lancet. 1994;344:1025–1026. [PubMed] [Google Scholar]

167. Mato R, deLancestre H, Carraher M, Roberts R B, Tomasz A. Multiplicity of genetic backgrounds among vancomycin-resistant Enterococcus faecium isolates recovered from an outbreak in a New York City Hospital. Microb Drug Resist. 1996;2:309–317. [PubMed] [Google Scholar]

168. Mekonen E T, Noskin G A, Hacek D M, Peterson L R. Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium. Microbl Drug Resist. 1995;1:249–253. [PubMed] [Google Scholar]

169. Mercier R C, Houlihan H H, Rybak M J. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrob Agents Chemother. 1997;41:1307–1312. [PMC free article] [PubMed] [Google Scholar]

170. Mobarakai N, Quale J M, Landman D. Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1994;38:385–387. [PMC free article] [PubMed] [Google Scholar]

171. Moellering R C, Jr, Weinberg A N. Studies on antibiotic synergism against enterococci. II. Effect of various antibiotics on uptake of 14C-labelled streptomycin by enterococci. J Clin Investig. 1971;50:2580–2584. [PMC free article] [PubMed] [Google Scholar]

172. Moellering R C, Jr, Wennersten C. Therapeutic potential of rifampin in enterococcal infections. Rev Infect Dis. 1983;5(Suppl. 3):528–532. [PubMed] [Google Scholar]

173. Moellering R C., Jr Emergence of enterococcus as a significant pathogen. Clin Infect Dis. 1992;14:1173–1178. [PubMed] [Google Scholar]

174. Moellering R C., Jr The Garrod lecture. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J Antimicrob Chemother. 1991;28:1–12. [PubMed] [Google Scholar]

175. Moellering R C. Antimicrobial susceptibility of enterococci: in vitro studies of the action of the antibiotics alone or in combination. In: Bisno A L, editor. Treatment of infective endocarditis. New York, N.Y: Grune & Stratton; 1981. pp. 81–96. [Google Scholar]

176. Montecalvo M A, deLancestre H, Carraher M, Gedris C, Chung M, Van Horn K, Wormser G P. Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol. 1995;16:680–685. [PubMed] [Google Scholar]

177. Montecalvo M A, Horowitz H, Gedris C, Carbonaro C, Tenover F C, Issah A. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother. 1994;38:1363–1367. [PMC free article] [PubMed] [Google Scholar]

178. Montecalvo M A, Seiter K, Carbonaro C A. Effect of novobiocin-containing antimicrobial regimens on infection and colonization with vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1995;39:794. [PMC free article] [PubMed] [Google Scholar]

179. Montecalvo M A, Shay D K, Patel P, Tacsa L, Maloney S A, Jarwis W R. Blood stream infections with vancomycin-resistant enterococci. Arch Intern Med. 1996;156:1458–1462. [PubMed] [Google Scholar]

180. Moreno F, Grota P, Crisp C, Magnon K, Melcher G P, Jorgenson J H, Patterson J E. Clinical and molecular epidemiology of vancomycin-resistant Enterococcus faecium during its emergence in a city in Southern Texas. Clin Infect Dis. 1995;21:1234–1237. [PubMed] [Google Scholar]

181. Morris J G, Jr, Shay D K, Hebden J N, McCarter R J, Jr, Perdue B E, Jarwis W, Johnson T A, Dowling T C, Polish L B, Schwalbe R S. Enterococci resistant to multiple antimicrobial agents, including vancomycin: establishment of endemicity in a university medical center. Ann Intern Med. 1995;123:250–259. [PubMed] [Google Scholar]

182. Murray B E. β-Lactamase-producing enterococci. Antimicrob Agents Chemother. 1992;36:2355–2359. [PMC free article] [PubMed] [Google Scholar]

183. Murray B E. Antibiotic resistance among enterococci: current problems and management strategies. In: Remington J S, Swartz M N, editors. Current clinical topics in infectious diseases. Boston, Mass: Blackwell Scientific Publications; 1989. pp. 94–117. [PubMed] [Google Scholar]

184. Reference deleted.

185. Murray B E. The life and times of the enterococcus. Clin Microbiol Rev. 1990;3:45–65. [PMC free article] [PubMed] [Google Scholar]

186. Murray B E. Vancomycin-resistant enterococci. Am J Med. 1997;101:284–293. [PubMed] [Google Scholar]

187. Nachtman A, Verma R, Egnor M. Vancomycin-resistant Enterococcus faecium shunt infection in an infant: an antibiotic cure. Microb Drug Resist. 1995;1:95–96. [PubMed] [Google Scholar]

188. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Publication M7-A4. 4th ed. Wayne, Pa: National Committee for Clinical Laboratory Standards; 1999. [Google Scholar]

189. Navarro F P. Courvalin. Analysis of genes encoding d-alanine–d-alanine ligase related enzymes in Enterococcus casseliflavus and Enterococcus flavescens. Antimicrob Agents Chemother. 1994;38:1788–1793. [PMC free article] [PubMed] [Google Scholar]

190. Neu H C, Chin N X, Niu W W. In vitro activity of the new glycopeptide decaplanin. Eur J Clin Microbiol Infect Dis. 1992;11:458–462. [PubMed] [Google Scholar]

191. Nicas T I, Cole C T, Preston D A, Schabel A A, Nagarajan R. Activity of glycopeptides against vancomycin-resistant gram-positive bacteria. Antimicrob Agents Chemother. 1989;33:1477–1481. [PMC free article] [PubMed] [Google Scholar]

192. Nicoletti G, Boghossian V, Borland R. Hygienic hand disinfection: a comparative study with chlorhexidine detergents and soap. J Hosp Infect. 1990;15:323–337. [PubMed] [Google Scholar]

193. Noble W C, Virani K, Cree R G A. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett. 1992;93:195–198. [PubMed] [Google Scholar]

194. Norris A H, Reilly J P, Edenstein P H, Brennon P J, Schuster M G. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis. 1995;20:1137–1144. [PubMed] [Google Scholar]

195. Noskin G A, Stosor V, Cooper I, Peterson L R. Recovery of vancomycin-resistant enterococci on fingertips and environmental surfaces. Infect Control Hosp Epidemiol. 1995;16:577–581. [PubMed] [Google Scholar]

196. Reference deleted.

197. O'Donovan C A, Fan-Havard P, Tecson-Tumang F T, Smith S M, Eng R H. Enteric eradication of vancomycin-resistant Enterococcus faecium with oral bacitracin. Diagn Microbiol Infect Dis. 1994;18:105–109. [PubMed] [Google Scholar]

198. Ostrowsky B E, Venkataraman L, D'Agata E M C, Gold H S, DeGirolami P C, Samore M H. Vancomycin-resistant enterococci in intensive care units. Arch Intern Med. 1999;159:1467–1472. [PubMed] [Google Scholar]

199. Ostrowsky B E, Clark N C, Thuvin-Eliopoulos C, Venkataraman L, Samore M H, Tenover F C, Eliopoulos G M, Moellering R C, Jr, Gold H S. A cluster of VanD vancomycin-resistant Enterococcus faecium: molecular characterization and clinical epidemiology. J Infect Dis. 1999;180:1177–1185. [PubMed] [Google Scholar]

200. Palmer S M, Rybak M J. Vancomycin-resistant enterococci. Pharmacotherapy. 1996;16:819–829. [PubMed] [Google Scholar]

201. Papanicolaou G A, Meyers B R, Meyers J, Mendelson M H, Lou S, Emre S, Miller C. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis. 1996;23:760–766. [PubMed] [Google Scholar]

202. Patel R, Rouse M S, Piper K E, Cockerill III F R, Steckelberg J M. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 1998;30:89–92. [PubMed] [Google Scholar]

203. Patel R, Uhl J R, Kohner P, Hopkins M K, Steckelberg J M, Kline B, Cockerill F R., III DNA sequence variation within vanA, vanB, vanC-1, and vanC-2/3 genes of clinical Enterococcus isolates. Antimicrob Agents Chemother. 1998;42:202–205. [PMC free article] [PubMed] [Google Scholar]

204. Patterson J E, Sweeney A H, Simms M, Carley N, Mangi R, Sabetta J, Lyons R W. Analysis of 110 series enterococcal infections. Medicine. 1995;74:191–200. [PubMed] [Google Scholar]

205. Paulssen J, Eidem T, Kristiansen R. Perforations in surgeons' gloves. J Hosp Infect. 1988;11:82–85. [PubMed] [Google Scholar]

206. Perichon B, Reynolds P, Courvalin P. VanD type glycopeptide-resistant Enterococcus faecium BM4339. Antimicrob Agents Chemother. 1997;41:2016–2018. [PMC free article] [PubMed] [Google Scholar]

207. Piddock L J V. New quinolones and gram-positive bacteria. Antimicrob Agents Chemother. 1994;38:163–169. [PMC free article] [PubMed] [Google Scholar]

208. Poyart C, Pierre C, Quesne G, Pron B, Berche B, Trieu-Cuot P. Emergence of vancomycin resistance in the genus Streptococcus: characterization of a vanB transferable determinant in Streptococcus bovis. Antimicrob Agents Chemother. 1997;41:24–29. [PMC free article] [PubMed] [Google Scholar]

209. Quale J, Ladman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis. 1996;23:1020–1025. [PubMed] [Google Scholar]

210. Reference deleted.

211. Quale J M, Landman D, Mobarakai N. Treatment of experimental endocarditis due to multidrug-resistant Enterococcus faecium with ciprofloxacin and novobiocin. J Antimicrob Chemother. 1994;34:797–802. [PubMed] [Google Scholar]

212. Quintiliani R, Jr, Courvalin P. Conjugal transfer of the vancomycin resistance determinant vanB between enterococci involves the movement of large genetic elements from chromosome to chromosome. FEMS Microbiol Lett. 1994;119:359–364. [PubMed] [Google Scholar]

213. Quintiliani R, Jr, Evers S, Courvalin P. The vanB gene confers various levels of self-transferable resistance to vancomycin enterococci. J Infect Dis. 1993;167:1220–1223. [PubMed] [Google Scholar]

214. Reference deleted.

215. Reynolds P E, Depardieu F, Dutka-Malen S, Arthur M, Courvalin P. Glycopeptide resistance mediated by enterococcal transposon Tn1546 requires production of VanX for hydrolysis of d-alanyl-d-alanine. Mol Microbiol. 1994;13:1065–1070. [PubMed] [Google Scholar]

216. Reynolds P E, Snaith H E, Maguire A J, Dutka-Malen S, Courvalin P. Analysis of peptidoglycan precursors in vancomycin-resistant E. gallinarum BM4174. Biochem J. 1994;301:5–8. [PMC free article] [PubMed] [Google Scholar]

217. Reference deleted.

218. Rosato A, Pierre J, Billot-Klein D, Buu-Hoi A, Gutmann L. Inducible and constitutive expression of resistance to glycopeptides and vancomycin dependence in glycopeptide-resistant Enterococcus avium. Antimicrob Agents Chemother. 1995;39:830–833. [PMC free article] [PubMed] [Google Scholar]

219. Ruoff K L, de la Maza L, Murtagh M J, Spargo J D, Ferraro M J. Species identities of enterococci isolated from clinical specimens. J Clin Microbiol. 1990;28:434–437. [PMC free article] [PubMed] [Google Scholar]

220. Rybak M J, Bailey E M, Lamp K C, Kaatz G W. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob Agents Chemother. 1992;36:1109–1114. [PMC free article] [PubMed] [Google Scholar]

221. Sahm D F, Free L, Handwerger S. Inducible and constitutive expression of vanC-1-encoded resistance to vancomycin in Enterococcus gallinarum. Antimicrob Agents Chemother. 1995;39:1480–1484. [PMC free article] [PubMed] [Google Scholar]

222. Sahm D F, Koburow G T. In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy. Antimicrob Agents Chemother. 1989;33:71–77. [PMC free article] [PubMed] [Google Scholar]

223. Samner E A, Reynolds P E. Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob Agents Chemother. 1990;34:413–419. [PMC free article] [PubMed] [Google Scholar]

224. Sanchez M L, Wenzel R P, Jones R N. In vitro activity of decaplanin (M86-1410), a new glycopeptide antibiotic. Antimicrob Agents Chemother. 1992;36:873–875. [PMC free article] [PubMed] [Google Scholar]

225. Reference deleted.

226. Satake S, Clark N, Rimland D, Nolte F S, Tenover F C. Detection of vancomycin-resistant enterococci in fecal samples by PCR. J Clin Microbiol. 1997;35:2325–2330. [PMC free article] [PubMed] [Google Scholar]

227. Schaberg D R, Culver D H, Gaynes R P. Major trends in the microbial etiology of nosocomial infection. Am J Med. 1991;91(Suppl. 3B):72S–75S. [PubMed] [Google Scholar]

228. Schleifer K H, Kilpper-Balz R. Transfer of Streptococcus faecalis and Streptococcus faecium to the genus Enterococcus nom. rev. as Enterococcus faecalis comb. nov. and Enterococcus faecium comb. nov. Int J Syst Bacteriol. 1984;34:31–34. [Google Scholar]

229. Schwalbe R S, McIntosh A C, Qaiyumi S, Johnson J A, Johnson R J, Farness K M, Holloway W J, Steele-Moore L. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob Agents Chemother. 1996;40:2416–2419. [PMC free article] [PubMed] [Google Scholar]

230. Shay D K, Maloney S A, Montecalvo M, Banerjee S, Wormser G P, Arduino M J, Bland R A, Jarwis W R. Epidemiology and mortality risk of vancomycin-resistant enterococcal blood stream infections. J Infect Dis. 1995;172:993–1000. [PubMed] [Google Scholar]

231. Shekar R, Chico G, Bass S N, Strozewsky K, Biddle J. Household transmission of vancomycin-resistant Enterococcus faecium. Clin Infect Dis. 1995;21:1511–1512. [PubMed] [Google Scholar]

232. Sherman J M. The streptococci. Bacteriol Rev. 1937;1:3–97. [PMC free article] [PubMed] [Google Scholar]

233. Shinabarger D L, Marotti K R, Murray R W, Lin A H, Merchior E P, Swaney S M, Dunyak D S, Demyan W F, Boysse J M. Mechanism of action of oxazolidinones on translation reactions. Antimicrob Agents Chemother. 1997;41:2132–2136. [PMC free article] [PubMed] [Google Scholar]

234. Shonekan D, Mildvan D, Handwerger S. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD 127,391 against blood isolates of gram-positive cocci. Antimicrob Agents Chemother. 1992;36:1570–1572. [PMC free article] [PubMed] [Google Scholar]

235. Slaughter S, Hayden M K, Nathan C, Hu T C, Rice T, Van Voorhis J, Matushek M, Franklin C, Weinstein R A. A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin-resistant enterococci in a medical intensive care unit. Ann Intern Med. 1996;125:448–456. [PubMed] [Google Scholar]

236. Soriano F, Zapardiel J, Roblas-Fernandez R. Comparative in vitro activity of the new glycopeptide SK&F 1104662 against problematic gram-positive bacteria. Eur J Clin Microbiol Infect Dis. 1991;10:782–784. [PubMed] [Google Scholar]

237. Soumerai S B, Avorn J, Taylor W C, Wessels M, Maher D, Hawley S L. Improving choice of prescribed antibiotics through concurrent reminders in an educational order form. Med Care. 1993;31:552–558. [PubMed] [Google Scholar]

238. Soumerai S B, McLaughlin T J, Avorn J. Quality assurance for drug prescribing. Qual Assur Health Care. 1990;2:37–58. [PubMed] [Google Scholar]

239. Speer B S, Shoemaker N B, Salyers A A. Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance. Clin Microbiol Rev. 1992;5:387–399. [PMC free article] [PubMed] [Google Scholar]

240. Stratton C W, Weeks L S. Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies. Diagn Microbiol Infect Dis. 1990;13:245–252. [PubMed] [Google Scholar]

241. Swenson J M, Clarck N C, Ferraro M J, Sahm D F, Doern G, Pfaller M A, Teller L B, Weinstein M P, Zabransky R J, Tenover F C. Development of a standardized screening method for detection of vancomycin-resistant enterococci. J Clin Microbiol. 1994;32:1700–1704. [PMC free article] [PubMed] [Google Scholar]

242. Swenson J M, Ferraro M J, Sahm D F, Charache P, Tenover F C. New vancomycin disk diffusion breakpoints for enterococci. The National Committee for Clinical Laboratory Standards Working Group on Enterococci. J Clin Microbiol. 1992;30:2525–2528. [PMC free article] [PubMed] [Google Scholar]

243. Tally F T, Ellestad G A, Testa R T. Glycylcyclines: a new generation of tetracyclines. J Antimicrob Chemother. 1995;35:449–452. [PubMed] [Google Scholar]

244. Tenover F C, Tokar F C, Swenson J, Paul S, Spitalny K, Jarwis W. Ability of clinical laboratories to detect antimicrobial resistant enterococci. J Clin Microbiol. 1993;31:1695–1699. [PMC free article] [PubMed] [Google Scholar]

245. Testa R T, Peterson P F, Jacobus N V, Sum P, Lee V J, Tally F. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother. 1993;37:2770–2777. [PMC free article] [PubMed] [Google Scholar]

246. Thauvin C, Eliopoulos G M, Willey S, Wennesten C, Moellering R C. Continuous infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother. 1987;31:139–143. [PMC free article] [PubMed] [Google Scholar]

247. Tornieporth N G, Roberts R B, John J, Hafnier A, Riley L W. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis. 1996;23:767–772. [PubMed] [Google Scholar]

248. Uttley A H C, Collins C H, Naidoo J, George R C. Vancomycin-resistant enterococci. Lancet. 1988;i:57–58. [PubMed] [Google Scholar]

249. Van der Auwera P, Pensart N, Korten V, Murray B E, Leclercq R. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis. 1996;173:1229–1236. [PubMed] [Google Scholar]

250. Wade J, Baille L, Rolando N, Casewell M. Pristinamycin for Enterococcus faecium resistant to vancomycin and gentamicin. Lancet. 1992;339:312–313. [PubMed] [Google Scholar]

251. Wade J J, Dessai N, Casewell M W. Hygienic hand disinfection for the removal of epidemic vancomycin-resistant Enterococcus faecium and gentamicin-resistant Enterobacter cloacae. J Hosp Infect. 1991;18:211–218. [PubMed] [Google Scholar]

252. Wade J J. The emergence of Enterococcus faecium resistant to glycopeptides and other standard agents—a preliminary report. J Hosp Infect. 1995;30(Suppl.):483–493. [PubMed] [Google Scholar]

253. Weinstein J W, Tallapragada S, Farrel P, Dembry L M. Comparison of rectal and perirectal swabs for detection of colonization with vancomycin-resistant enterococci. J Clin Microbiol. 1996;34:210–212. [PMC free article] [PubMed] [Google Scholar]

254. Reference deleted.

255. Wells C L, Juni B A, Cameron S B, Mason K R, Dunn D L, Fernieri P, Rhame F S. Stool carriage, clinical isolation and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis. 1995;21:45–50. [PubMed] [Google Scholar]

256. Westenfelder G O, Paterson P Y, Reisberg B E, Carlson G M. Vancomycin-streptomycin synergism in enterococcal endocarditis. JAMA. 1973;223:37–40. [PubMed] [Google Scholar]

257. Whitman M S, Pitsakis P G, Zausner A, Livornese L, Osborne A J, Johnson C C, Levison M E. Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1993;37:2069–2073. [PMC free article] [PubMed] [Google Scholar]

258. Reference deleted.

259. Williamson R, Colderwood S B, Moellering R C, Tomasz A. Studies on the mechanism of intrinsic resistance to β-lactam antibiotics in group D streptococci. J Gen Microbiol. 1983;129:813–822. [PubMed] [Google Scholar]

260. Witte W, Klare I. Glycopeptide-resistant Enterococcus faecium outside the hospitals: a commentary. Microb Drug Resist. 1995;1:259–263. [PubMed] [Google Scholar]

261. Woodford N, Johnson A P, Morrison D. Current perspectives on glycopeptide resistance. Clin Microbiol Rev. 1995;8:585–615. [PMC free article] [PubMed] [Google Scholar]

262. Wu Z, Wright G D, Walsh C T. Overexpression, purification and characterization of VanX, a d-,d-dipeptidase which is essential for vancomycin resistance in Enterococcus faecium BM4147. Biochemistry. 1995;34:2455–2463. [PubMed] [Google Scholar]

263. Yamaguchi E, Valena F, Smith S M, Simons M- A, Eng R H K. Colonization pattern of vancomycin-resistant Enterococcus faecium. Am J Infect Control. 1994;22:202–206. [PubMed] [Google Scholar]

264. Yamane N, Jones R N. In vitro activity of 43 antimicrobial agents tested against ampicillin-resistant enterococci and gram-positive species resistant to vancomycin. Diagn Microbiol Infect Dis. 1994;14:337–345. [PubMed] [Google Scholar]

265. Zaman M M, Landman D, Burney S, Quale J M. Treatment of experimental endocarditis due to multi-drug resistant Enterococcus faecium with clinafloxacin and penicillin. J Antimicrob Chemother. 1996;37:127–132. [PubMed] [Google Scholar]

266. Reference deleted.

267. Zervos M J, Kauffman C D, Thrasse P M, Bergman A G, Mikesell T S, Schaberg D R. Nosocomial infection by gentamicin-resistant Streptococcus faecalis: an epidemiological study. Ann Intern Med. 1987;106:687–691. [PubMed] [Google Scholar]

Page 2

Intrinsic and acquired antimicrobial drug resistance in enterococcia

Intrinsic resistance
 β-Lactams (particularly cephalosporins and penicillinase-resistant penicillins)
 Low concentrations of aminoglycosides
Acquired resistance
 High concentrations of β-lactams, through alteration of PBPs or production of β-lactamase
 High concentrations of aminoglycosides
 Glycopeptides (vancomycin, teicoplanin)
 Fusidic acid